initi buy pt deep-div
tale launch platform massiv leverag
unusu market cap biotech market
product new launch next mo model leverag possibl break
even next year two major pipelin platform think investor
miss one big thing- leverage- launch go better expect
stock move lot
project revenu ahead consensu believ launch
product next year signific driver revenu growth compani
project total revenu vs street consensu
compani project
beat consensu stock could go lot
expect leverag come abl use commerci
team sell multipl product need big sale forc
sell orphan diseas product bull case assum
probabl four product launch also use conserv oper
margin assumpt peak base case model
combin adjust peak sale tegsedi waylivra ptc-aadc
peak sale risdiplam adjust peak royalti
done deep dive pipelin believ compani two
platform gener great product growth capabl ad
significantli leverag stock pg
strh take gene therapi platform see great strateg
invest though first indic aadc small believ
treat patient enough recov cost platform compani
expect identifi patient launch valu potenti
poc data next indic
strh take splice platform platform allow
discov small molecul modifi diseas central nervou
system differenti small molecul highli competit vs
drug oral system cross bbb platform
limit diseas caus defect splice hd poc data
valuat risk
pt deriv use probability-adjust dcf use
discount rate termin valu project probability-adjust
peak sale tegsedi waylivra risdiplam
aadc risk stock includ inabl commerci
build commerci team gene therapi platform inabl compet
sma market receiv regulatori approv market product
neg read-through lead splice program deeper pipelin
tr target
pt deriv probability-adjust dcf
manag know scienc commit mission
founder ceo stuart peltz phd
guidanc financi
valu potenti bn
ptc-aadc
price assumpt ptc-aadc approv gene therapi
market model ptc-aadc
controversi pushback
page
splice basic intro splice
splice know relev player functiongo deeper
believ risdiplam work lead indic sma
sma type look line competitor
sma type type data point clinic meaning benefit believ oral
formul advantag
huntington diseas differ biolog small molecul moa still
hunt begun huntington
natur histori data offer benchmark data readout length repeat offer predictor
diseas progress
page
receiv regulatori approv market product
neg read-through lead splice program deeper pipelin
inabl commerci build commerci team gene therapi platform
inabl compet sma market
page
strh/bull/bearstrh casebul casebear casefair valuepric target us eupeak sale us eupeak sale launch selltegsedilaunch latin americaadjust peak sale latin americaadjust peak sale launch sellwaylivralaunch latin americaadjust peak sale latin americaadjust peak sale launch sellrisdiplamlaunch us euadjust peak sale us euadjust peak sale launch sell therapeut inc
believ lot synergi leverag benefit stock
synergi abl use commerci team sell multipl product
two platform drug discoveri benefit orphan
model suggest stock sensit revenu growth compani
beat expect see signific movement bull case
valu stock launch sale expect product go well
believ conserv expens assumpt offer room
bottom-lin growth
believ highli differenti peer less market cap
market cap less believ highli unusu product
tegsedi waylivra latin america adjust peak sale
compani first gene therapi product ptc-aadc us eu peak sale
risdiplam royalti adjust peak royalti
incom addit revenu stream also believ differenti
abil quickli reach break-even
project possibl break-even
differ
believ launch product next year signific driver revenu growth
compani
project total revenu vs factset consensu
done deep dive pipelin believ compani two platform
gener great product growth capabl ad significantli leverag stock
gene therapi platform great strateg invest though first indic
aadc small believ treat patient enough recov cost compani
expect identifi patient launch valu potenti bn
splice platform allow compani discov small molecul modifi
splice central nervou system differenti small molecul
highli competit vs drug platform limit diseas caus
valuat risk
pt deriv use probability-adjust dcf use discount rate believ
appropri risk associ smid-cap biotech compani use termin valu given
pipelin potenti project probability-adjust peak sale tegsedi
 waylivra risdiplam aadc probabl reflect market risk approv
risk view
page
pt deriv adjust dcf
pt deriv probability-adjust dcf
pt deriv use probability-adjust dcf use discount rate believ appropri risk associ smid-cap
biotech compani use termin valu given pipelin potenti project probability-adjust peak sale tegsedi
waylivra risdiplam aadc probabl reflect market risk approv risk view
figur million dollar except per share data
page
assumpt model-aadctegsediwaylivrarisdiplamadjust peak sale free projectionsgaap ebit stock base depreci work capit capit free valu growth rate valu valu outstand valu per valu per compani report strh estim inc
figur million except per share data
compani report strh research
page
incom product adjustedrevenu -fa hd product acquir oper excl itemsinterest expens expens incom incom loss exc spec tax incom ep non-gaap adjust stock-bas one time restructur stock-bas one time restructur fair valu defer conting incom share outstand share outstand share dilut use non-gaap inc
figur million except per share data
compani report strh research
page
balanc assetscash cash receiv expens current current asset asset liabilitiesaccru portion long-term current consider current consider consider tax long-term stockhold liabil inc
figur million except per share data
compani report strh research
page
flow from/ use oper activ net reconcil net loss net cash use depreci valuat defer conting interest discount premium invest debt issuanc compens foreign currenc transact loss gain dispos defer incom oper asset liabil trade receiv expens current payabl accru cash provid by/ use oper flow from/ use invest activ purchas fix market redempt market product acquisit net cash cash provid by/ use invest flow from/ use financ activ payment long-term exercis share issu employe stock purchas issuanc cost relat convert proce public issuanc convert cash provid by/ use financ exchang rate chang increase/ decreas cash cash cash equival begin cash equival end inc
near-term readout look sma data
figur near-term larg impact catalyst sma program within next month
page
productdescriptiontherapeut platformrisdiplamsmal molecul splice modifi spinal muscular atrophi sma phase sunfish confirmatori part data present type non-ambulatori conf phase firefish confirmatori part primari analysi type infant rainbowfish pre-symptomat week file base part firefish file base part firefish file japan diseas moleculesmal molecul huntingtin splice modifi huntington diseas hd select therapy- aadcaav deliv aadc genearomat l-amino acid decarboxylas aadc deficiencysubmit bla file aadc file aadc deliv frataxin fxn genefriedreich ataxia fa file progress first franchisetranslarnasmal molecul suppressor nonsens mutationsnonsens mutationduchenn muscular dystrophi updat chmp opinion dystrophin dystrophin long-term outcom studi productswaylivraantisens triglycerid apolipoprotein c-iii apoc-iii famili partial lipodystrophi fpl updat time file latin inc
phase sunfish confirmatori part data present med confer type non-ambulatori yo
phase firefish confirmatori part primari analysi type infant
updat progress first patient treat gene therapi ptc-fa friedreich ataxia fa
initi clinic data huntington program
nda file risdiplam spinal muscular atrophi sma
bla file ptc-aadc aromat l-amino acid decarboxylas aadc defici
ind file ptc-fa friedreich ataxia fa
small molecul splice platform enter clinic huntington diseas hd
gene therapi product ptc-aadc us eu
licens tegsedi launch brazil
licens waylivra launch brazil
risdiplam launch commerci partner roch rog-ch nr
dmd franchis product translarna launch us
page
compani descript global commercial-stag biotech compani two
research platform one gene therapi splice focus rare diseas
compani two commerci drug duchenn muscular dystrophi dmd multipl gene therapi
product multipl splice modifi oncolog program partnership rare diseas revenu
growth come abil grow sale dmd emflaza translarna well gain
market approv sale gene therapi splice platform compani found
allan steven jacobson stuart peltz march headquart south
drug market addit drug next year expect addit
product market ptc-aadc tegsedi waylivra risdiplam addit product
clinic huntington diseas hd friedreich ataxia fa
guid revenu probabl adjust revenu vs
street
figur street total revenu
strh research factset
market soon-to-b market medicin
emflaza gener guid
translarna gener ex-u guid us ex-u
page
tegsedi hattr amyloidosi launch latin america
guid tegsedi waylivra
waylivra file latin america soon
guid tegsedi waylivra
ptc-aadc bla file expect guid gene
therapi platform ptc-fa expect enter clinic late
manag know scienc commit mission
founder ceo stuart peltz phd
dr peltz found serv ceo sinc
prior professor depart molecular genet microbiolog robert wood
dr peltz receiv phd univers wisconsin
emili hill join novemb
prior director ir warner chilcott respons lead function
prior senior manag ir genzym corpor
ms hill tuft univers school biomed research
prior execut director market np pharmaceut
mr souza hold mba fundao dom cabral brazil
dr almstead join
prior project manag procter gambl
dr almstead receiv phd univers illinoi urbana-champaign
dr pykett join
prior ceo ceo navidea biopharmaceut presid ceo
alser pharmaceut
dr pykett receiv phd univers pennsylvania
page
figur manag compens align well sharehold interest
overal compens plan appear line sharehold interest name execut offic
elig earn incent bonu base individu perform goal well corpor goal
relat product develop advanc clinic studi compens
execut structur around achiev corpor goal mileston year
base subject object perform goal determin board director
page
approv product duchenn muscular dystrophi dmd four possibl launch
splice modifi huntington diseas gene therapi friedreich ataxia enter clinic
figur pipelin focus rare diseas develop main modal small molecul
gene therapi
page
guidanc financi
guid bn revenu
figur guidanc includ revenu
page
deal acquisit
april acquir right emflaza marathon pharmaceut
paid up-front
compris approxim cash approxim
common stock subject maximum share limit shortfal
made whole addit cash consider
marathon entitl receiv low percentag base
blend averag basi net sale
paid up-front cash approxim common stock
subject estim maximum million share limit shortfal made
whole addit cash consider
potenti futur consider includ develop mileston
success-bas mileston well tier commerci mileston
annual net sale friedreich ataxia angelman syndrom
august enter collabor licens agreement akcea nr
commerci tegsedi waylivra product contain compound
countri latin america caribbean
paid up-front paid earlier fda ema
approv waylivra
pay akcea regulatori mileston territori latin america
caribbean total
akcea elig receiv royalti percent rang net sale
drug territori
page
mileston payment royalti akcea receiv tegsedi split
ioni akcea waylivra mileston payment royalti
akcea receiv split ioni nr
may therapeut enter suppli agreement mri intervent mric nr
neurosurg devic current futur gene therapi program
strateg equiti invest purchas share mri common stock
intend initi clinic trial mitochondri epilepsi bioelectron
advanc compound earli next year also intend explor use consid
anti-inflammatori properti compound expect disclos
near futur
paid bioelectron total up-front consider fund cash hand
less transact expens incur bioelectron ii amount outstand
indebted bioelectron includ loan advanc bioelectron plu accru
unpaid interest thereon iii held escrow account secur
potenti indemnif oblig owe compani
page
gene therapi platform aadc fa
strateg invest bla file first gene therapi candid aadc success
provid valid platform near-term revenu
believ acquisit good strateg invest
ad gene therapi pipelin add anoth modal diversifi pipelin
expand differ indic
fit well compani focu rare diseas
near-term potenti increas revenu
success approv aadc increas confid platform
aadc defici lead program bla expect launch
though rare believ data highli support offer straight rout
market help expertis screen
friedreich ataxia fa expect enter clinic late
page
gene therapi platform aadc fa
valu potenti bn
note potenti address market gene therapi platform
figur roadmap potenti address market
need know
lead gene therapi program high unmet need
expect bla follow late
guid gene therapi platform
expect exclus market period us
believ data highli support approv aadc defici expect approv
launch
approv would increas confid success indic within gene
current cur therapi aadc defici current care palli
chang earli childhood mortal
though aadc rare connect commun expertis patient
page
gene therapi platform aadc fa
believ high unmet need aadc defici address gene therapi aadc
defici caus mutat result loss function aadc gene believ
make aadc defici amend cur treatment deliveri function gene gene
therapi cur therapi aadc defici current care palli
patient us market
strh take believ like address us patient base
acquisit price agili price gene therapi product estim
treatment patient alon pay acquisit platform upsid
believ data aadc defici highli support approv show therapi
clear efficaci well-toler
believ data highli support
natur histori studi show patient abl
improv valid scale
studi went patient year age
sever diseas lead death year age
complet studi show ptc-aadc provid improv aim
well-toler
page
gene therapi platform aadc fa
figur infant sever aadc defici develop mileston motor skill
figur natur histori studi aadc patient show lack motor develop
page
startenddeltaconclusionmedian age year year year median follow-up period yearsmedian aim impli aadcd patient show improv aimsmedian impli aadcd patient show improv controlnatur histori studi aadc defici patient develop full head control sit abil stand abil speech none show improv point live inc
gene therapi platform aadc fa
figur complet clinic trial show ptc-aadc restor motor function patient
figur improv score help valid qualit improv motor
page
month latermedian aim score controlpati year old bedridden head controlhead control month sit unassist month stand support month patient year old bedridden head controlgood head controlpati year old bedridden head controlgood head controlpati year old bedridden head controlhead control month sit assist month phase month laterfollow-upmedian aim score score controlpati year old head controlparti head controlassess age year sit stroller reach toy yrspatient year old head controlparti head controlassess age year sit stroller reach toy yrspatient year old head controlparti head controlassess age year sit stroller reach toy yrspatient year old head controlgood head control sit without support stand supportassess age year stand support move around stand without support briefli learn walk eat yrspatient year old head controlgood head control sit support brieflyassess age year sit yrpatient year old head controlparti head controlassess age year sit stroller reach toy yrspatient year old head controlgood head control sit support briefli n/an/apati year old head controlgood head control sit support brieflyassess age year sit well stand support eat yrpatient year old head controlgood head control sit support brieflyassess age year sit support eat yrpatient year old head controlgood head control sit support brieflyassess age year sit well move around learn stand eat hand say word yrphase therapeut inc
gene therapi platform aadc fa
ptc-aadc complet two trial taiwan one on-going trial enrol dose
two complet studi single-arm open-label intervent
trial enrol patient believ standard diagnost metric use studi
studi use decreas homovanil acid hva -hydroxyindoleacet acid elev
l-dopa cerebrospin fluid csf presenc one aadc gene mutat
presenc clinic symptom diagnosi enrol patient older age patient
evalu monthli safeti everi month efficaci use peabodi development motor
scale second edit alberta infant motor scale aim valid scale
assess motor skill young children
follow administr ptc-aadc patient show signific improv baselin
figur aim total score maintain baselin patient
function movement fail achiev motor mileston includ head control sit
stand capabl expect base publish natur histori sever aadc defici
post-treat patient demonstr de novo dopamin product post-
treatment full head control sit unassist post-treat stand
support accord publish natur histori studi patient expect
achiev motor mileston
ptc-aadc well toler advers event occur surgic procedur advers
event gener associ diseas state frequent advers event associ
ptc-aadc involuntari motor movement complet resolv time seriou
advers event attribut ptc-aadc
third on-going trial treat patient set treat
patient treat patient three trial
expect approv launch exclus market period us base
biolog price competit innov act
end-of-phas meet juli fda indic clinic non-clin
data suffici support submiss bla without addit trial guid
submit bla late anticip commerci launch
protocol assist meet april ema also indic current clinic non-
clinic data suffici support submiss without addit trial guid
submit follow bla submiss
pursu patent protect -aadc
page
gene therapi platform aadc fa
patient aromat lamino acid decarboxylas aadc defici symptom appear first
year life experi development delay lead patient bedridden
depend lifelong care sever form lead death age aromat lamino acid
decarboxylas protein requir synthesi neurotransmitt dopamin
serotonin dopamin key neurotransmitt requir develop proper function act
within base region brain known striatum striatum critic compon motor
ptc-aadc
gene therapi ptc-aadc use adeno-associ viru type one-tim deliveri
function aadc gene directli striatum specif putamen striatum via bilater
putaminalinfus dose vector genom vg
though aadc preval low believ acquisit program see develop
expertis patient screen help patient identif
preval aadc defici estim patient world-wide newborn
incid world-wide higher preval found patient southern chines descent
especi taiwan japan due founder variant
enter collabor agreement nation taiwan univers ntu
sept research clinic develop ntu respons research clinic trial
agili respons fund acquir agili august ad gene therapi platform
pipelin
price assumpt ptc-aadc approv gene therapi
assum price ptc-aadc
bluebird nr zynteglo approv eu price
novarti novn-ch nr zolgensma price annual
spark/roch luxturna mutation-associ retin dystrophi price
page
gene therapi platform aadc fa
market model ptc-aadc
strh research compani report
page
-aadc aromat l-amino acid decarboxylas aadc deficiency-aadc aadc defici patient high risk live rate high risk us patient live aadc patient screen new us patient prior-year patient identifi us patient market penetr us aadc patient receiv non-u aadc patient receiv us aadc revenu increas check -aadc aadc defici popul patient live rate high risk eu patient live aadc patient screen eu patient prior-year patient identifi eu patient market eu aadc patient receiv non-u aadc patient receiv eu aadc revenu increas aadc defici row patient live aadc patient fli us patient go us patient fli eu patient go eu revenu inc
gene therapi platform aadc fa
believ success aadc defici posit read-through platform
believ fa good target gene therapi
need know
fa part gene therapi platform ind file expect late
fa rare genet disord patient global incid us
impair motor function symptom usual appear age
current cur therapi fa current care aim reliev symptom
fa due loss frataxin protein
figur ptc-fa increas frataxin target level pig non-human primat
page
look success sma catalyst valid platform
success spinal muscular atrophi sma greatli increas confid platform
acknowledg hd sma differ underli biolog
believ splice platform highli differenti among therapi target
offer advantag oral administr discoveri small molecul
oppos antisens oligo
platform leverag mani diseas limit defect splice
expertis platform set high barrier entri difficult competitor
controversi pushback
strh take acknowledg fair point/risk await data sma type
controversi doesnt lot patient data
type believ data hold page
controversi sma type trial uncontrol
pathophysiolog sma give us confid page
controversi weight-bas oral pill difficult give
strh take acknowledg fair point believ natur histori molecular biolog
drug risdiplam given liquid formul babi
babi make smallest percentag sma market
intrathec administr problem intrathec fatigu high cost associ
deliveri
better brain penetr small oral molecul compar larger non-or molecul
oligo benefit oral formul anecdot comment kol highlight
concern lack brain-penetr may respons difficulti swallow
depend feed tube
lack long-term durabl data gene therapi option concern hurt
uptak gene therapi babi speak parent physician note
reoccur concern
page
page
drugspinrazarisdiplamzolgensmamechanismincreas smn splice increas smn splice increas smn ad splice splice gene replacementdrug typeasosmal moleculegen therapydrug load dose mainten dose everi monthsonc dailyon timebodi distribut onlysystemicsystemictarget populationapprov typesal typesapprov children intrathec fatigu resourc requir intrathec administr facil cost good safeti far enough efficaci safeti data weight-bas dose could difficult administ liver tox dilut effect reimburs narrow patient popul preclin fraud inc
figur program comparison data believ sma data support splice
platform hd differ biolog sma
compani report strh research
page
indicationsmahdetiologyloss gene result depend express genehtt gene repeatsgen involv exon exclud gene repeatsproteininsuffici proteinproduct toxic protein aggregatesrnaineffici splicingno splice abormalitiessplic siteregularli splice regularli splice either wt mutanttreat goalsincreas bindingincreas bindingspl goalincreas splice effici exon splice effici pseudoexonrna goalinclud exon htt rna levelsprotein goalincreas smn protein productionreduc htt protein levelsmedian increas smn protein increasemean increas smn protein brain mean reduct htt csf baselin control mg/ kg mg/kg mg/kg mice mean increas smn protein peripher blood control mg/ kg mg/kg mg/kg blood cell mice bachd mice sma type improv chop-intendsma type clinic data pt achiev improv preclinicaloutcom measur clinic outcom see inc
figur catalyst sma
figur catalyst hd
need know
small molecul sma clinic confirmatori part data expect within next month bla file
base current data
deep dive think success sma increas confid platform
understand what import splice
platform leverag understand splice
molecular biolog pathophysiolog diseas indic
compar contrast platform appli
page
drug classdrugtarget patient populationphas type part data present med conf small molecul oral risdiplamsma type part primari efficaci analysessma type initi datamyostatin inhibitor iv type pk/pd dataphas updat long-term datagen therapi iv zolgensmaphas updat datapre-sym sma type updat datagen therapi intrathec zolgensmasma type updat datapoc studi sma top-line poc studysmal molecul oral firdapsesma type interim month top-line month datasmal molecul oral branaplam type initl datasma type sunfish sma type firefish sma type classcompanytarget patient populationpreclinicalphas gener data select mt wave life sciencesearli antisenseuniqureearli antisens select mt voyag therapeuticsn/aind file expect late modifiern/aexpect enter clinic repressor select mt sangamo therapeuticsn/apublish preclin data juli preclin data preclin developmentphas data initi biomark data inc
splice basic intro splice
defect splice caus diseas target splice valid mean treat
splice tightli regul cellular process modifi precursor messeng rna pre-mrna
convert mrna mrna use make protein splice pre-mrna
cellular process take place product protein dysfunct process splice
produc aberr nonfunct protein reduc protein level convers fix aberr
process increas restor protein function level thu defect splice lead
human diseas target splice process treat underli diseas
figur splice target valid
target splice valid approach treat underli diseas figur list
diseas relat splice approv treatment target splice therapi
target splice approv util antisens oligonucleotid aso modifi splice
buy spinraza approv spinal muscular atrophi
nr exondi approv duchenn muscular dystrophi
page
diseas caus defect splicingcompanyfamili dysautonomia fd experiment enter clinic late moleculespin muscular atrophi sma approvedspinraza nusinersen antisens oligonucleotid aso biogenexperiment nda file risdiplamsmal moleculeduchenn muscular dystrophi dmd approvedexondi eteplirsen antisens oligonucleotid aso sarepta therapeuticsmedium-chain acyl-coa dehydrogenas mcad deficiencyhutchinson-gilford progeria syndrom hgp myoton dystrophi type type domin retin pigmentosa rp microcephal steodysplast primordi dwarfism type taybi-lind syndrom tal frontotempor dementia congenit muscular dystrophi fcmd amyotroph later sclerosi al hypercholesterolemiacyst fibrosi cf treatment target splice inc
platform highli differenti difficult other replic
larg compound librari certain know-how believ make harder
player capabl includ
compound librari note compound small molecul
integr system high-throughput screen compounds/ week chemic
optim lead hit
intellectu properti around technolog collect refer gene express
modul small molecul
strong understand splice site
target splice believ system target rna biolog gener
develop translarna small molecul allow ribosom read
platform allow compani discov small molecul modifi
splice central nervou system
like platform discoveri small molecul aim splice believ develop
small molecul help differenti player also target splice
use antisens oligonucleotid aso viral deliveri gene silenc
small molecul bypass blood-brain barrier allow compound administ
small molecul effect diffus advantag disord
like evenli distribut higher probabl affect everi neuron
view oral administr advantag
patient familiar could help uptak particularli patient
uncomfort concept gene therapi invas rout administr
conveni could addit help uptak possibl payment reimburs
tissu support data sma unsur impact hd
page
robust splice modifi platform limit diseas caus
platform develop small molecul target splice believ
approach limit diseas caus splice believ platform use
treat diseas huntington diseas
discoveri focus develop small molecul target splice addit
two indic list
figur also go non-splicing-rel diseas plan enter small molecul
splice modifi platform huntington diseas immedi plan
enter splice modifi candid famili dysautonomia clinic late
also file nda risdiplam spinal muscular atrophi sma
figur sma lead indic nda expect
approv risdiplam help valid platform increas confid indic
believ success lead splice molecul risdiplam sma help valid platform
figur discov optim splice platform
rna level molecul share molecular goal target cellular
machineri stage splice program aim includ exon
program aim increas bind complex spliceosom
recognit stage splice differ three molecul target
target pre-mrna sequenc specif respect diseas believ
differ preclud platform gener effect candid
platform design discov specif molecul uniqu sequenc
molecul compel preclin data support act moa figur
look risdiplam approv uptak addit read-through
protein level sma aim produc protein hd goal
reduc protein level sma bind splice modifi risdiplam result increas
protein product mean treat underli diseas hd goal reduc
express toxic protein caus diseas
page
indicationcompoundpreclinicalnext milestonespin muscular atrophi sma risdiplamnda file diseas hd optim phaseexpect enter clinic modifi pipelin small molecul inc
figur data support platform develop small molecul capabl modifi
splice know relev player functiongo deeper
first link understand relationship sma read-through splice modifi target
complex pre-mrna recognit step
small molecul molecular mechan action moa increas binding/recognit
pre-mrna pre-mrna splice process gener messeng rna mrna use
protein product process region pre-mrna call intron splice cleav
region call exon join togeth produc final mrna
page
indicationsmahdetiologyloss gene result depend express genehtt gene repeatsgen involv exon exclud gene repeatsproteininsuffici proteinproduct toxic protein aggregatesrnaineffici splicingno splice abormalitiessplic siteregularli splice regularli splice either wt mutanttreat goalsincreas bindingincreas bindingspl goalincreas splice effici exon splice effici pseudoexonrna goalinclud exon htt rna levelsprotein goalincreas smn protein productionreduc htt protein levelsmedian increas smn protein increasemean increas smn protein brain mean reduct htt csf baselin control mg/ kg mg/kg mg/kg mice mean increas smn protein peripher blood control mg/ kg mg/kg mg/kg blood cell mice bachd mice sma type improv chop-intendsma type clinic data pt achiev improv preclinicaloutcom measur clinic outcom see inc
import splice machineri call spliceosom need abl recogn
exactli cut identifi correct two specif nucleotid cut everi
time achiev recognit use compon spliceosom known
complex spliceosom discuss focu complex recogn
bind sequenc pre-mrna start end intron known splice site
complex bind near termin end intron
specif target bind complex splice site current small
molecul highlight figur
figur specif target bind complex splice site
strh extra take current focus target see reason
target platform believ target would present futur upsid
expand new indic expect expand target part
spliceosom target success use leverag diseas exampl
rare diseas recal focus rare diseas caus aberr bind xeroderma
pigmentosum affect million person strh research khan sg et al
page
believ risdiplam work lead indic sma
expect approv broad label includ sma patient launch
data support nda file expect nda file first
total data understand sma biolog give us confid sma data hold part updat sma data
expect month
indic sma good fit target splice platform
sma safe de-risk first indic
sma biolog support address splice platform
risdiplam partner roch partner roch plan file nda
entitl tier royalti rang ww net sale guid royalti
page
drug classdrugtarget patient populationphas type part data present med conf small molecul oral risdiplamsma type part primari efficaci analysessma type initi datamyostatin inhibitor iv type pk/pd dataphas updat long-term datagen therapi iv zolgensmaphas updat datapre-sym sma type updat datagen therapi intrathec zolgensmasma type updat datapoc studi sma top-line poc studysmal molecul oral firdapsesma type interim month top-line month datasmal molecul oral branaplam type initl datasma type sunfish sma type firefish sma type inc
spinraza data give us confid updat risdiplam data hold support
spinraza posit read-through risdiplam
target region involv bind
target process recognit junction site exon
spinraza risdiplam differ drug class also differ molecular target
risdiplam spinraza target region pre-mrna involv splice
exon believ spinraza data approv strong read-through risdiplam although
differ molecular target target region involv bind
process recognit junction point exon intron
spinraza target sequenc pre-mrna inher limit antisens oligo play
role bind wherea risdiplam directli interact improv bind junction site
exon intron spinraza bind sequenc bit downstream bind
region term intron splice silenc normal recruit molecul
inhibit splice hnrnp prevent bind junction site spinraza
work bind region hnrnp inhibit bind result spinraza
indirectli improv bind thu improv exon splice effici produc full-
page
risdiplam discov develop select interact exon/intron junction
site bind risdiplam higher affin junction site allow
overcom inhibitori effect hnrnp
page
spinraza posit read-through risdiplam target region involv
bind process recognit junction point exon
intron risidiplam direct
page
figur spinraza valid target bind risidiplam directli
page
mutat sma patient caus depend effici splice sma address
improv splice valid
smn genet need know two copi smn gene call
produc smn protein amino acid sequenc except
mutat gene dna level one attribut
caus weaken splice effici exon mutat locat posit
exon mutat posit exon properli splice
includ final smn protein result truncat unstabl protein thu dysfunct
larg affect motor neuron silver line weaken
splice mean still produc small amount function smn despit
major time produc dysfunct truncat protein due weaken splice
exon gene produc dysfunct truncat smn protein time
full-length function smn protein time
care ineffici splice especi there gene
care gene gene loss inde caus diseas
spinal muscular atrophi sma mutat result loss sinc
gene produc smn protein rescu smn protein product
gene lost howev problem produc full-length
function smn protein time mean rescu sma patient one
two way high copi number improv splice effici
inde sma patient copi gene much better life
outcom later diseas outset three common type sma type
order increas diseas sever figur two less common type sever
result prenatal-onset death within week birth type adult-onset least
figur copi number improv diseas outcom sma patient
page
sma typesma type type type type sever common formsymptom onset monthssymptom onset onsetag symptom onset monthsabl sit/stand walkabl walk difficulti never abl sitmuscl weakness/skelet deformitiesmuscl weakness/skelet deform shor tlife expectancyshorten life expectancyclos normal life expect genesmost genesmost gene walk test hine motor milestoneshand held dynamometry/mmthammersmith expand cmapforc vital capacityhand held dynamometry/mmt biomarkerscmapforc vital capac biomark cmap biomark isi present juli measuresphenotyp inc
copi number strongli improv diseas outcom sma patient
improv diseas outcom ad new copi function smn gene
valid fda approv novarti zolgensma gene therapi
express smn protein aav deliveri
sma type affect infant month result babi never abl sit
without assist difficult breath life expect year mani requir
continu hr respiratori intervent sma type patient carri
one two copi
sma type affect patient month age patient abl sit
walk stand life expect rang year sma type
patient three copi
sma type patient also diseas onset month age abl walk
close normal life expect sma type patient three
four copi
sma type patient adult onset patient four six copi
improv splice effici also improv diseas outcom valid
discuss capabl produc full-length function smn protein
albeit time result ineffici splice thu second mean
improv smn protein level improv splice exon
approach valid fda approv biogen spinraza
sma type look line competitor
efficaci acknowledg difficulti cross-trial comparison
trial size larg believ data similar spinraza
believ updat risdiplam data like hold possibl regress similar efficaci
spinraza
risdiplam compar spinraza view zolgensma less compar
due differ moa
risidiplam well-toler look updat frequenc seriou advers
page
figur like comparable-to-bett chop-intend improv score sma type splice modifi
page
studyendearfirefish part part intrathec risdiplam oral pill zolgensma iv infus type infantile-onset sma type copi armsspinraza infant cohort low dose cohort high dose part data may first doserang daysmedian age enrol month rang dosingprimari endpointsproport respond improv motor mileston measur hine section efspart safeti toler pk/pdpart primari endpoint proport infant sit without support second month treatment assess gross motor scale bsid-iiiindepend sit ef monthsoutcom interim analysi spinraza vs untreat final analysi spinraza vs untreat summari month risdiplam tx motor mileston month infant infant cohort bcohort high abl sit without support sec infant abl stand support thier weight abl maintain upright head control chop-intend score reach month age experienc surviv without perman ventilationmean age recent visit month average follow-up time monthschop-intend score chop-intend march score increas average one month month gene therapi may intend improv spinraza vs perman ventil spinraza vs controlaft month risdiplam treatment infant aliv event-freeno patient requir perman aliv without perman ventilationdeath/perman ventil spinraza vs infant aliv month fed exclusvi via feed death unrel treatment occur month die respiratori failur dsmb deem unrel requir non-invas bipap ventil day time withdraw commentspulmonari function swallow babi requir tracheostomi reach perman ventil lost abil swallowsurviv therapeut inc
figur like comparable-to-bett motor improv sma type splice
figur risidiplam well-toler look updat frequenc seriou
page
spinrazarisdiplamzolgensmaendear studi post treatmentinf dose select confirmatori part zolgensma trial use sit second risdiplam least five second firefish sma type reaction risdiplamn tract sma type therapeut inc
sma type type data point clinic meaning benefit
believ oral formul advantag
risidiplam data sma type clinic meaning
pivot part phase sunfish studi
press releas announc primari endpoint met pivot
part phase sunfish studi
statist signific improv overal studi popul
withdraw due treatment-rel safeti find
data present expect medic meet possibl sma
eu feb may
part sunfish show clinic meaning improv motor function
measur mfm score
underli moa risidiplam understand sma biolog give us confid
clinic benefit real
oral formul give advantag risdiplam market vs competitor
refer back
page
figur comparing/contrast sma drug page detail comparison
compar drug sma type harder due underli pathophysiolog
use differ scale complic cross-trial comparison
type slower progress depend larger time scale
page
figur differ scale complic data comparison improv motor function measur mfm score
page
part part on-going strongtreatmentspinraza intrathec spinraza intrathec risdiplam oral pill zolgensma intrathec sma type later-onset sma type sma type type copi spinraza untreat later-onsetsma type type sma type sma type first median age rang month dosingprimari endpointschang hfmse score monthsmean hfmse upper limb modul ulm walk test dose-find follow oleprimari endpoint safeti toler pk/pdexploratori efficacypart efficaci safeti select dose placebo-control monthsprimari endpoint mfmprimari efficaci outcom month stand without support chang hfmse baselineoutcom measureschang hfmse month improv motor function vs declin untreatedproport children chang hfmse score hfmse respond vs untreatedchang baselin rulm upper limb function score month spinraza vs untreat ulm score nearli nearli type reach avgerag ulm score max score nearli improv walk abil individu treat spinraza least achiev signific improv abil walk mean hfmse sma type sma type sma type assess nonambul sma type sma type gain abil walk independentlypart baselin pt achiev chang month among among total mfm chang baselin mean sd pt achiev improv sit mean month post-treat mean age score respond month mileston achiev median month f/u month dose crawl pt stand indep stand went ot walk walk assistancecom part efficaci endpoint chang baselin total scorestudi closeout anticip sept result pt exclusionari antibodi titer screen inc
huntington diseas differ biolog small molecul moa
still
molecular level approach huntington diseas increas bind promot exon
inclus differ hd biolog warrant investig
what hd program
molecul splice molecular mechan action directli bind
increas bind pre-mrna
indic
molecul optim oral administ penetr blood-brain barrier
what differ hd program
though target differ hd biolog mostli warrant investig
aim includ unwant exon call pseudoexon normal includ
figur hd differ sma goal biolog
controversi relat hd
safeti concern reduc wildtyp htt gene
approach work
target repeat vs exon vs pseudoexon
despit differ hd program like hd program
platform perspect believ success valid abil leverag
platform expand beyond disord caus exon exclus possibl
treat disord caus splice ineffici reduc protein level
page
indicationsmahdetiologyloss gene result depend express genehtt gene repeatsgen involv exon exclud gene repeatsproteininsuffici proteinproduct toxic protein aggregatesrnaineffici splicingno splice abormalitiessplic siteregularli splice regularli splice either wt mutanttreat goalsincreas bindingincreas bindingspl goalincreas splice effici exon splice effici pseudoexonrna goalinclud exon htt rna levelsprotein goalincreas smn protein productionreduc htt protein level inc
diseas perspect believ platform offer compound hd highli
differenti drug believ offer strong valu proposit
overal believ platform capabl discov oral compound improv
splice brain thu capabl treat disord relat exon exclus next
question whether leverag platform disord caus exon
exclus believ hd help us address
page
hunt begun huntington
though yet enter clinicexpect enter clinic differenti offer strong valu proposit
reduc concern time market
need know
approv drug treat symptom none approv treat underli diseas
figur two approv therapi neither treat underli diseas
figur roch lead aso uniqur voyag develop gene therapi differenti behind
safeti concern reduc wildtyp htt gene
approach work
target repeat vs exon vs pseudoexon
page
drug classcompanydrug namegener nameapprovalindicationvesicular monoamin transport vmat associ hdvesicular monoamin transport vmat inhibitorteva pharmaceuticalaustedodeuterium-substitut associ hdapprov therapi treat symptom diseasedrug classcompanytarget patient populationpreclinicalphas gener data select mt wave life sciencesearli antisenseuniqureearli antisens select mt voyag therapeuticsn/aind file expect late modifi therapeuticsn/aexpect enter clinic repressor select mt sangamo therapeuticsn/apublish preclin data juli preclin data preclin developmentphas data initi biomark data modifi drug clinic therapeut inc
approach differenti differenti offer advantag treatmentreduc
concern time market
competitor includ target rna sangamo target dna unlik
competitor develop antisens rna instead develop small
molecul target rna wherea antisens oligo use sequenc specif directli htt
rna small molecul target htt rna interact cellular machineri
process rna use protein product call splice interact
splice machineri spliceosom develop drug specif recogn htt rna
preserv advantag featur small molecul benefit antisens oligo
splice modifi platform gener small molecul wherea everyon els use
antisens protein
small molecul bypass blood-brain barrier allow compound
small molecul effect diffus like evenli distribut
throughout brain higher probabl affect everi neuron import
everi untreat neuron would chanc death mutat
huntingtin cerebrospin fluid csf may restrict antisens oligonucleotid
outer surfac brain
view oral administr advantag
patient familiar could help uptak particularli patient
uncomfort concept gene therapi invas rout
conveni could addit help uptak possibl payment
peripher tissu unsur impact hd outsid
hd commonli consid diseas mass new studi
brought attent patholog peripher tissu note
cardiomyocyt skelet muscl hd patient exhibit high rate
cardiac event lead heart failur whether link mutat htt
express cardiomyocyt uncertain effect striat muscl limit
preclin hd model
page
therapi target underli diseas aim cellular process occur protein
product htt
string compound test hd possibl disease-modifi treatment none
success far tetrabenazin deutetrabenazin deuterated-modifi tetrabenazin
approv motor impair chorea associ hd market xenazin lundbeck
lun-dk nr austedo teva teva hold gilbert respect note neither target
underli diseas none target mutant gene directli respons hd instead target
network protein interact mutant gene
gene caus hd mutat call huntingtin htt gene encod htt
protein drug develop taken aim target gene fashion differ
canon approach rather directli target gene protein therapi
aim target cellular process take place product huntingtin
page
though hd part splice program hd caus defect splice
huntington diseas hd huntington diseas neurodegen disord caus
expand repeat gene encod huntingtin protein htt mutant form htt
contain repeat repeat highli penetr genet diagnosi median
age onset year age individu repeat patient
repeat earlier onset around year age classifi juvenil hd case
individu usual less repeat hd autosom domin diseas
mean individu need one copi mutant htt develop hd
figur length repeat correl onset aggress diseas
estim hd affect peopl unit state current treatment option
abl treat symptom need cur therapi hd becom ever import
popul age advanc understand etiolog hd hd diseas model
believ hd address underli diseas target directli believ
target hd best direct cellular process occur product protein
sever competitor clinic target underli diseas like
differenti among bunch believ differenti would help captur market share
page
natur histori data offer benchmark data readout length repeat
offer predictor diseas progress
natur histori data earli stage earli manifest hd patient show
caudat volum reduc within window baselin statist
comparison measur month measur detect statist
signific month volum reduc
putamen reduc volum month report compar statist
month measur detect statist signific month volum reduc
motor function also worsen month indic point increas
uhdr total motor score tm
point increas month uhdr decreas point
month point month
stage earli manifest patient progress stage month
progress stage moder manifest
initi stage earli manifest patient progress stage moder manifest
progress stage
need know
stage hd divid premanifest manifest
stage prior clinic onset motor diagnosi
stage diagnosi motor deficit
gener divid stage
earli moder advanc may also subdivid stage use
numer represent advanc
stage larg descript necessarili predic biolog
event case diseas stage cancer differ
three stage manifest rel perform daili function work
drive summar follow
gener still activ area function often still abl work drive
unabl perform complex function independ work drive still abl
take care activ daili live adl simpl household task
longer abl perform adl without help
page
stage manifest larg descript unifi hd rate scale uhdr
commonli use assess hd clinic
sever diseas progress correl length repeat longer repeat
also associ earlier onset diseas median age onset year age
individu repeat estim repeat alon determin
variat patient variat age onset suggest factor
genet environment contribut significantli progress hd sever gene
propos genet modifi hd none withstood scrutini thu may still hard
predict actual rate progress
page
figur natur progress hd
page
believ stage earli manifest hd could benefit splice modifi
model revenu build see data learn regulatori path
hd may add later stage hd patient
estim incid hd western popul arriv estim
patient hd unit state line report estim base two
larg observ studi europ registri studi particip premanifest
manifest hd patient north america cohort studi premanifest
manifest hd patient take conserv estim hd patient stage
earli manifest hd guid enter clinic model launch
page
global sale two product expect grow
dmd franchis provid sourc revenu
help establish rare diseas
help commerci sale effort futur drug
translarna get us approv late eu approv
strh take nda resubmiss translarna larg regulatori issu resubmiss
nda contain new data gener dystrophin product quantifi procedur
agre upon fda
need know
fda provid translarna appeal fda reiter stanc
expect resubmit nda includ dystrophin data suggest fda
quantifi procedur agre upon two parti
phase long-term outcom studi could serv confirmatori post-approv trial
requir connect acceler approv pathway
guidanc dmd franchis revenu guidanc
two three approv therapi dmd
catalyst nda resubmiss
guid
sale ex-u
oral small molecul help ribosom read nonsens mutat
approv eu nonsens mutat duchenn muscular dystrophi nmdmd
enrol phase patient nonsens mutat dravet
expect complet await updat
guid sale
sale
page
oral glucocorticoid treatment dmd patient year
phase placebo-control studi expect result
competit dmd
sarepta market exondi antisens oligo report sale
catalyst dmd landscap look
page
antisens oligocompani repli deacetylas hdac inhibitorphas pharmaceuticalsraxonecoenzym therapeut inc
product launch latin america within next month
figur licens product launch latin america within next month
page
drugtegsedi inotersen waylivra volanesorsen indicationhereditari transthyretin hattr amyloidosisfamili chylomicronemia syndrom fc famili partial lipodystrophi fpl drug classantisenseantisensetargettransthyretintriglycerid apolipoprotein c-iii apoc-iii launch brazil latin americaupd file mn commerci right latin america caribbean akcea august inc
global commercial-stag biotech compani two research platform
one gene therapi splice focus rare diseas compani two
commerci drug duchenn muscular dystrophi dmd multipl gene therapi product multipl
splice modifi oncolog program partnership rare diseas revenu growth come
abil grow sale dmd emflaza translarna well gain market
approv sale gene therapi splice platform compani found allan
steven jacobson stuart peltz march headquart south plainfield nj
buy unusu market cap biotech stock market product
product launch month lot model leverag possibl break even next
year two major platform could deliv pipelin next year think investor
miss one big thing- leverage- launch go better expect stock move lot
model sale ahead consensu use conserv oper margin given small
sale forc need overlap market product could upsid margin better
model see dataset sma fredrick ataxia huntington catalyst
valuat risk
pt deriv use probability-adjust dcf use discount rate believ
appropri risk associ smid-cap biotech compani use termin valu
given pipelin potenti project probability-adjust peak sale
tegsedi waylivra risdiplam aadc risk stock includ inabl
commerci build commerci team gene therapi platform inabl compet sma
market receiv regulatori approv market product neg read-through
lead splice program deeper pipelin
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
